drugset / Trial / NCT01356602

Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

NCT01356602

Phase 3 Completed 397 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.

Timeline

Start
2011-05
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 150 mg Subcutaneous
Comparator Triamcinolone Acetonide Other / unclassified 40 mg Intramuscular

Indications